255 related articles for article (PubMed ID: 25320012)
1. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.
Parikh F; Duluc D; Imai N; Clark A; Misiukiewicz K; Bonomi M; Gupta V; Patsias A; Parides M; Demicco EG; Zhang DY; Kim-Schulze S; Kao J; Gnjatic S; Oh S; Posner MR; Sikora AG
Cancer Res; 2014 Dec; 74(24):7205-16. PubMed ID: 25320012
[TBL] [Abstract][Full Text] [Related]
2. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
3. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
4. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
6. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.
Wansom D; Light E; Worden F; Prince M; Urba S; Chepeha DB; Cordell K; Eisbruch A; Taylor J; D'Silva N; Moyer J; Bradford CR; Kurnit D; Kumar B; Carey TE; Wolf GT
Arch Otolaryngol Head Neck Surg; 2010 Dec; 136(12):1267-73. PubMed ID: 21173378
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
8. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
[TBL] [Abstract][Full Text] [Related]
9. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
10. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.
Economopoulou P; Koutsodontis G; Avgeris M; Strati A; Kroupis C; Pateras I; Kirodimos E; Giotakis E; Kotsantis I; Maragoudakis P; Gorgoulis V; Scorilas A; Lianidou E; Psyrri A
PLoS One; 2019; 14(5):e0215984. PubMed ID: 31071126
[TBL] [Abstract][Full Text] [Related]
11. Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients.
Bhatt KH; Neller MA; Srihari S; Crooks P; Lekieffre L; Aftab BT; Liu H; Smith C; Kenny L; Porceddu S; Khanna R
J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32716518
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes.
Oh JE; Kim JO; Shin JY; Zhang XH; Won HS; Chun SH; Jung CK; Park WS; Nam SW; Eun JW; Kang JH
Int J Oncol; 2013 Aug; 43(2):383-93. PubMed ID: 23708675
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
16. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.
Anderson KS; Gerber JE; D'Souza G; Pai SI; Cheng JN; Alam R; Kesiraju S; Chowell D; Gross ND; Haddad R; Gillison ML; Posner M
Oral Oncol; 2015 Aug; 51(8):751-8. PubMed ID: 26094591
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
19. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
20. CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis.
Jung AC; Guihard S; Krugell S; Ledrappier S; Brochot A; Dalstein V; Job S; de Reynies A; Noël G; Wasylyk B; Clavel C; Abecassis J
Int J Cancer; 2013 Jan; 132(2):E26-36. PubMed ID: 22890882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
